For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
35
views
12
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      479
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A 35‐year‐old male patient was diagnosed with stage IIC skin melanoma that rapidly progressed after surgery. Treatment was continued with radiotherapy, which did not stop further spread of disease and the patient was put on a combination of nivolumab and Rigvir. Subsequently, the progression has slowed.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

          Igor Puzanov, Mohammed Milhem, David Minor … (2016)
          Combining immunotherapeutic agents with different mechanisms of action may enhance efficacy. We describe the safety and efficacy of talimogene laherparepvec (T-VEC; an oncolytic virus) in combination with ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 checkpoint inhibitor) in patients with advanced melanoma.
          Article 0 comments Cited 239 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Maximizing tumor immunity with fractionated radiation.

            Dörthe Schaue, Josephine A. Ratikan, Keisuke S. Iwamoto … (2012)
            Technologic advances have led to increased clinical use of higher-sized fractions of radiation dose and higher total doses. How these modify the pathways involved in tumor cell death, normal tissue response, and signaling to the immune system has been inadequately explored. Here we ask how radiation dose and fraction size affect antitumor immunity, the suppression thereof, and how this might relate to tumor control. Mice bearing B16-OVA murine melanoma were treated with up to 15 Gy radiation given in various-size fractions, and tumor growth followed. The tumor-specific immune response in the spleen was assessed by interferon-γ enzyme-linked immunospot (ELISPOT) assay with ovalbumin (OVA) as the surrogate tumor antigen and the contribution of regulatory T cells (Tregs) determined by the proportion of CD4(+)CD25(hi)Foxp3(+) T cells. After single doses, tumor control increased with the size of radiation dose, as did the number of tumor-reactive T cells. This was offset at the highest dose by an increase in Treg representation. Fractionated treatment with medium-size radiation doses of 7.5 Gy/fraction gave the best tumor control and tumor immunity while maintaining low Treg numbers. Radiation can be an immune adjuvant, but the response varies with the size of dose per fraction. The ultimate challenge is to optimally integrate cancer immunotherapy into radiation therapy. Copyright © 2012 Elsevier Inc. All rights reserved.
            Article 0 comments Cited 237 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Combining radiation and immunotherapy: a new systemic therapy for solid tumors?

              Chad Tang, Xiaohong Wang, Hendrick Soh … (2014)
              With the recent success of checkpoint inhibitors and other immunomodulating agents, there has been renewed interest in the combination of such agents with radiation. The biologic premise behind such a strategy is that the tumor-antigen release achieved by localized radiation will promote specific tumor targeting by the adaptive immune system, which can be augmented further by systemic immune-stimulating agents. In this manner, clinicians hope to induce a phenomenon known as the abscopal effect, whereby localized radiation results in immune-mediated tumor regression in disease sites well outside of the radiation field. Herein, we present a comprehensive overview of the early clinical and preclinical evidence behind this approach.
              Article 0 comments Cited 114 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Andra Tilgase:
                ORCID: https://orcid.org/0000-0002-3385-5182
                andra.tilgase@rigvir.com
                Journal
                Journal ID (nlm-ta): Clin Case Rep
                Journal ID (iso-abbrev): Clin Case Rep
                Journal ID (doi): 10.1002/(ISSN)2050-0904
                Journal ID (publisher-id): CCR3
                Title: Clinical Case Reports
                Publisher: John Wiley and Sons Inc. (Hoboken )
                ISSN (Electronic): 2050-0904
                Publication date (Electronic): 08 May 2019
                Publication date Collection: June 2019
                Volume: 7
                Issue: 6 ( doiID: 10.1002/ccr3.2019.7.issue-6 )
                Pages: 1191-1196
                Affiliations
                [ 1 ] AmberLife Cancer Clinic Jūrmala Latvia
                [ 2 ] Rigvir Rīga Latvia
                [ 3 ] Department of Radiology Pauls Stradiņš Clinical University Hospital Rīga Latvia
                [ 4 ] National Center of Pathology Affiliate of Vilnius University Hospital Santaros Klinikos Vilnius Lithuania
                Author notes
                [*] [* ] Correspondence

                Andra Tilgase, Rigvir, Teātra iela 9, LV‐1050 Riga, Latvia.

                Email: andra.tilgase@ 123456rigvir.com

                Author information
                https://orcid.org/0000-0002-3385-5182
                https://orcid.org/0000-0001-9585-9288
                Article
                Publisher ID: CCR32182
                DOI: 10.1002/ccr3.2182
                PMC ID: 6552946
                PubMed ID: 31183092
                SO-VID: cdfafb2f-d698-4347-a660-06b4de56e9b0
                Copyright © © 2019 Rigvir. Clinical Case Reports Published by John Wiley & Sons Ltd.
                License:

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                Date received : 19 October 2018
                Date revision received : 01 April 2019
                Date accepted : 16 April 2019
                Page count
                Figures: 6, Tables: 0, Pages: 6, Words: 3035
                Categories
                Subject: Case Report
                Subject: Case Reports
                Custom metadata
                source-schema-version-number 2.0
                component-id ccr32182
                cover-date June 2019
                details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.4 mode:remove_FC converted:06.06.2019

                Keywords: combination treatment,metastatic melanoma,nivolumab,oncolytic virus,rigvir
                Data availability:
                Keywords: combination treatment, metastatic melanoma, nivolumab, oncolytic virus, rigvir

                Comments

                Comment on this article

                scite_

                Similar content479

                See all similar

                Cited by1

                See all cited by

                Most referenced authors380

                See all reference authors